Breaking Down Nanjing King-Friend Biochemical Pharmaceutical Co., Ltd Financial Health: Key Insights for Investors

Nanjing King‑Friend Biochemical's latest numbers tell a story of contrasts that every investor should parse: total revenue in 2024 was 3.92 billion yuan (down 0.20% year-on-year) while Q1 2025 revenue slid 11.85% to 885.22 million yuan, yet trailing twelve‑month revenue as of March 31, 2025, still rose to 3.80 billion yuan (+4.86%); profitability also surprised with a 2024 net income of 826.1 million yuan (a remarkable +536.09% jump) even as market valuation sits at a market cap of 17.77 billion yuan and a trailing P/E of 25.23 (forward P/E 15.21), and material headwinds appear - notably a ~45% drop in heparin API revenue and >50% decline in CDMO revenues in H1 2025 - making the company's debt metrics (D/E ~0.32), dividend policy (0.10 yuan/share), buyback authorization (CNY 40 million) and analyst projections (net income to 1.06 billion yuan in 2025, consensus revenue 4.764 billion CNY) critical data points to weigh as you read on.

Nanjing King-Friend Biochemical Pharmaceutical Co., Ltd (603707.SS) - Revenue Analysis

• 2024 Total Revenue: 3.92 billion yuan (-0.20% vs 2023)
• Q1 2025 Revenue: 885.22 million yuan (-11.85% YoY)
• TTM Revenue (as of 2025-03-31): 3.80 billion yuan (+4.86% vs prior TTM)
• Revenue per employee: ~2.80 million yuan (1,360 employees)
• Price-to-Sales (P/S): 4.67
• Market Capitalization (2025-07-02): 17.77 billion yuan

Nanjing King-Friend Biochemical Pharmaceutical Co., Ltd (603707.SS) - Profitability Metrics

Nanjing King-Friend Biochemical Pharmaceutical Co., Ltd (603707.SS) delivered notable profitability improvements across 2024-2025, driven by stronger margins, improved returns, and resumed shareholder distributions.

• 2024 net income: 826.10 million yuan (increase of 536.09% vs. 2023)
• TTM net income (as of 2025-03-31): 649.83 million yuan; diluted EPS (TTM): 0.40 yuan
• Profit margin: 19.28%
• Operating margin: 11.47%
• Return on assets (ROA): 5.77%
• Return on equity (ROE): 11.69%
• Declared annual dividend: 0.10 yuan per share; payable on 2025-06-05

For context on strategic direction and corporate priorities that may influence future profitability, see: Mission Statement, Vision, & Core Values (2026) of Nanjing King-Friend Biochemical Pharmaceutical Co., Ltd.

Nanjing King-Friend Biochemical Pharmaceutical Co., Ltd (603707.SS) - Debt vs. Equity Structure

Key balance-sheet and valuation metrics as of Q3 2024 and market update to September 29, 2025:

• Total assets: 250 million USD (Q3 2024)
• Total liabilities: 80 million USD (Q3 2024)
• Debt-to-equity ratio: 0.32 (indicating relatively low leverage)
• Enterprise value / Revenue (EV/Rev): 4.75
• Enterprise value / EBITDA (EV/EBITDA): 17.50
• Price-to-book (P/B): 2.73
• Trailing P/E: 25.23
• Forward P/E: 15.21
• Market capitalization: decreased 11.79% over the past year - from ¥18.99 billion to ¥16.80 billion (as of 2025-09-29)

Investor-focused observations:

• The low debt-to-equity ratio (0.32) points to conservative leverage and greater balance-sheet flexibility for capital allocation or R&D investment.
• P/B of 2.73 implies the market places a sizeable premium over book value, reflecting intangible assets, growth expectations, or competitive positioning.
• EV/Revenue of 4.75 and EV/EBITDA of 17.50 show the company is valued at a multiple consistent with mid-to-high growth specialty pharmaceutical peers; EV/EBITDA = 17.5 explicitly signals the market is paying 17.5x normalized cash operating earnings.
• The divergence between trailing P/E (25.23) and forward P/E (15.21) indicates the market expects meaningful earnings acceleration ahead.
• The ~11.8% decline in market cap over the past year warrants monitoring of share-price drivers despite stable underlying leverage metrics.

For a broader investor context and shareholder composition, see: Exploring Nanjing King-Friend Biochemical Pharmaceutical Co., Ltd Investor Profile: Who's Buying and Why?

Nanjing King-Friend Biochemical Pharmaceutical Co., Ltd (603707.SS) - Liquidity and Solvency

Available public disclosures and the provided briefing do not include many standard short-term and long-term solvency metrics for Nanjing King-Friend Biochemical Pharmaceutical Co., Ltd (603707.SS). Below are the specific items and their reported availability.

• Current ratio: not specified in the available data.
• Quick ratio: not provided.
• Interest coverage ratio: unavailable.
• Operating cash flow (latest period): not detailed.
• Debt-to-assets and other solvency ratios: not available.
• Ability to meet long-term obligations: not explicitly detailed.

Investors seeking clarity should request or review the company's latest consolidated balance sheet, income statement, and cash flow statement to compute these metrics, and can read further context here: Exploring Nanjing King-Friend Biochemical Pharmaceutical Co., Ltd Investor Profile: Who's Buying and Why?

• Immediate next data to obtain: audited financial statements, notes on debt maturities, and interim cash flow reports.
• Analyses to perform once data is obtained: compute current and quick ratios, interest coverage, debt-to-equity/asset ratios, and free cash flow trends.

Nanjing King-Friend Biochemical Pharmaceutical Co., Ltd (603707.SS) - Valuation Analysis

• TTM revenue: 3.80 billion yuan (as of 2025-03-31)
• Market capitalization: 17.77 billion yuan (3/31/2025 measurement)
• P/S ratio: 4.67
• Trailing P/E: 25.23
• Forward P/E: 15.21 - implies the market is pricing in near-term earnings growth
• P/B ratio: 2.73 - equity valued at a premium to book
• EV/Revenue: 4.75
• EV/EBITDA: 17.50
• Market cap change (1y): -11.79% - from 18.99 billion yuan to 16.80 billion yuan (as of 2025-09-29)

• Interpretation notes: the spread between trailing P/E (25.23) and forward P/E (15.21) indicates the market expects meaningful earnings improvement; P/B >1 signals a premium over book value; EV/EBITDA of 17.50 positions the company at a relatively elevated multiple versus many peers in specialty pharma/biochemicals.
• For corporate background and how the business generates revenue, see: Nanjing King-Friend Biochemical Pharmaceutical Co., Ltd: History, Ownership, Mission, How It Works & Makes Money

Nanjing King-Friend Biochemical Pharmaceutical Co., Ltd (603707.SS) - Risk Factors

Key downside pressures for Nanjing King-Friend are concentrated in its API and CDMO businesses, recent quarterly results, market valuation shifts, and execution risks as it navigates weak end-market demand and price pressure.

• Q1 2025 top-line pressure: revenue fell 11.85% year-on-year to ¥885.22 million, driven mainly by API weakness.
• Profit collapse: reported net income roughly halved year-on-year in Q1 2025, primarily attributable to the same API headwinds and margin compression.
• Heparin API slump: heparin API revenue declined ≈45% in H1 2025, materially reducing a historically important high-margin product line.
• CDMO deterioration: CDMO revenue declined by over 50% in H1 2025, indicating contract delays, lower utilization or client-side cutbacks.
• Equity market reaction: market capitalization fell from ¥18.99 billion to ¥16.80 billion over the past year (-11.79%) as of 2025-09-29.
• Valuation vs. expectations: trailing P/E = 25.23 while forward P/E = 15.21, implying the market expects earnings recovery but assigns a premium that could re-rate further if guidance misses.

Material risk channels to monitor:

• Concentration risk: dependency on heparin API and CDMO revenue streams-sharp declines in H1 2025 expose concentration vulnerabilities.
• Margin risk: API price erosion and lower CDMO utilization compress gross and operating margins, evident in the halving of net income in Q1 2025.
• Client and tender risk: loss or deferment of large contracts will disproportionately impact revenue given recent >50% CDMO fall.
• Regulatory and quality risk: any adverse regulatory action in API production (especially heparin) could trigger outsized earnings and reputational damage.
• Market re-rating risk: while forward P/E (15.21) assumes recovery, failure to meet earnings expectations could push the stock multiple lower and amplify the recent -11.79% market-cap decline.
• Liquidity and financing risk: weaker operating cash flow from falling revenues may constrain reinvestment in capacity or R&D unless management secures external financing on favorable terms.

For background on the company's history, ownership and business model, see: Nanjing King-Friend Biochemical Pharmaceutical Co., Ltd: History, Ownership, Mission, How It Works & Makes Money

Nanjing King-Friend Biochemical Pharmaceutical Co., Ltd (603707.SS) - Growth Opportunities

• Analysts project robust net income expansion: 1.06 billion CNY (2025), 1.41 billion CNY (2026), 1.84 billion CNY (2027) - implied year‑over‑year growth of 29%, 33%, and 30% respectively.
• Consensus revenue forecast for full‑year 2025: 4.764 billion CNY, signaling top‑line momentum into the mid‑2020s.
• Q2 2025 estimated EPS: 0.130 CNY, indicating quarter‑level profitability and potential earnings leverage as sales scale.
• April 2025 equity buyback authorization: 40 million CNY - management signaling confidence in intrinsic value and capital allocation flexibility.
• Product pipeline catalyst: liraglutide approval in April 2025 - expected to contribute incremental revenue and diversify therapeutic footprint.
• International expansion: foreign markets accounted for 76.75% of main business revenue in 2024, providing a large addressable market and FX/diversification benefits.

• Primary growth drivers:
  • New product commercialization (liraglutide) driving incremental sales and improved margin mix.
  • High exposure to foreign markets (76.75% of 2024 revenue) enabling scale and diversified demand channels.
  • Active capital return (40M CNY buyback) and earnings acceleration support investor confidence and potential EPS accretion.
• Operational levers to watch:
  • Commercial rollout speed and reimbursement/access for liraglutide across key markets.
  • Gross margin trajectory as product mix and international sales scale.
  • Execution of further M&A or licensing to complement international expansion.